The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: results of a multicenter phase II trial
    Sato, N.
    Iwata, H.
    Masuda, N.
    Nakamura, S.
    Yamamoto, N.
    Kuroi, K.
    Kurosumi, M.
    Tsuda, H.
    Akiyama, F.
    Toi, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 121 - 121
  • [42] Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide
    Sun, Weiling
    Li, Chunhong
    Liu, Meiyan
    Liu, Wei
    Yang, Chunyu
    Cai, Li
    ONCOLOGY LETTERS, 2016, 11 (03) : 2320 - 2326
  • [43] Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome
    Penault-Llorca, F.
    Radosevic-Robin, N.
    Abrial, C.
    Dauplat, M-M
    Weber, B.
    Mouret-Reynier, M-A
    Gligorov, J.
    Tredan, O.
    Privat, M.
    Uhrhammer, N.
    Desrichard, A.
    Bidet, Y.
    Cayre, A.
    Aube, C.
    Romero, P.
    Kwiatkowski, F.
    Chalabi, N.
    Bignon, Y-J
    Chollet, P.
    Nabholtz, J-M
    CANCER RESEARCH, 2013, 73
  • [44] Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer
    vonMinckwitz, G
    Heidemann, E
    Souchon, R
    Samonigg, H
    Hirschmann, WD
    Bodenstein, H
    Schindler, A
    Schulze, M
    Clemens, H
    Konig, M
    Scharl, A
    Fischer, JT
    Kaufmann, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 646 - 646
  • [45] The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D)
    Vulsteke, C.
    Pfeil, A. M.
    Schwenkglenks, M.
    Paridaens, R.
    Dieudonne, A. S.
    Pettengell, R.
    Hatse, S.
    Neven, P.
    Lambrechts, D.
    Wildiers, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S474 - S475
  • [46] Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
    Knoop, AS
    Knudsen, H
    Balslev, E
    Rasmussen, BB
    Overgaard, J
    Nielsen, KV
    Schonau, A
    Gunnarsdóttir, K
    Olsen, KE
    Mouridsen, H
    Ejlertsen, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7483 - 7490
  • [47] Feasibility study of fluorouracil/epirubicin/cyclophosphamicle (FEC75) followed by docetaxel (DOC) as adjuvant chemotherapy in Japanese patients with node positive breast cancer
    Rai, Y.
    Tanaka, M.
    Mitsuyama, M.
    Uga, T.
    Tanaka, S.
    Nanba, K.
    Furusawa, H.
    Murata, K.
    Nishimura, R.
    Oikawa, T.
    Kamada, Y.
    Maeda, S.
    Maeda, J.
    Honjyo, S.
    Iwase, H.
    Yamamoto, Y.
    Masuno, K.
    Shibuta, K.
    Kai, Y.
    Taniguchi, H.
    Yahara, T.
    Yokoyama, G.
    Yoshinaga, Y.
    Umeda, S.
    Hisamatsu, K.
    Tamura, K.
    BREAST, 2009, 18 : S54 - S54
  • [48] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
    Bonneterre, J
    Dieras, V
    Tubiana-Hulin, M
    Bougnoux, P
    Bonneterre, ME
    Delozier, T
    Mayer, F
    Culine, S
    Dohoulou, N
    Bendahmane, B
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1466 - 1471
  • [49] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
    J Bonneterre
    V Dieras
    M Tubiana-Hulin
    P Bougnoux
    M-E Bonneterre
    T Delozier
    F Mayer
    S Culine
    N Dohoulou
    B Bendahmane
    British Journal of Cancer, 2004, 91 : 1466 - 1471
  • [50] A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
    Jinno, H.
    Sakata, M.
    Hayashida, T.
    Takahashi, M.
    Mukai, M.
    Ikeda, T.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1262 - 1266
12345